[{"id":"73e92b8b-263d-4b85-959d-4edc90ccd9d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05485974","created_at":"2022-08-03T15:55:02.933Z","updated_at":"2024-07-02T16:35:37.299Z","phase":"Phase 1","brief_title":"A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation","source_id_and_acronym":"NCT05485974","lead_sponsor":"HUYABIO International, LLC.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sosimerasib (HBI-2438)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-09-13"}]